Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"

被引：1
作者：
Sullivan, Ivana [1 ]
Planchard, David [1 ]
机构：
[1] Gustave Roussy, Dept Med Oncol, 114 Rue Edouard Vaillant, F-94800 Villejuif, France
来源：
JOURNAL OF THORACIC DISEASE | 2016年 / 8卷 / 10期
关键词：
ADULT PATIENTS PTS; ALK-INHIBITOR; CONFER RESISTANCE; SINGLE-ARM; OPEN-LABEL; CRIZOTINIB; NSCLC; CERITINIB; CHEMOTHERAPY; MUTATIONS;
D O I：
10.21037/jtd.2016.10.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：E1287 / E1292
页数：6
相关论文
共 35 条
  • [1] [Anonymous], 2014, J THORAC ONCOL
  • [2] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
    Bergethon, Kristin
    Shaw, Alice T.
    Ou, Sai-Hong Ignatius
    Katayama, Ryohei
    Lovly, Christine M.
    McDonald, Nerina T.
    Massion, Pierre P.
    Siwak-Tapp, Christina
    Gonzalez, Adriana
    Fang, Rong
    Mark, Eugene J.
    Batten, Julie M.
    Chen, Haiquan
    Wilner, Keith D.
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Carbone, David P.
    Ji, Hongbin
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    Pao, William
    Iafrate, A. John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 863 - 870
  • [3] Taking Aim at ALK Across the Blood-Brain Barrier
    Camidge, D. Ross
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) : 389 - 390
  • [4] Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
    Camidge, D. Ross
    Kono, Scott A.
    Flacco, Antonella
    Tan, Aik-Choon
    Doebele, Robert C.
    Zhou, Qing
    Crino, Lucio
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (22) : 5581 - 5590
  • [5] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
    Choi, Young Lim
    Soda, Manabu
    Yamashita, Yoshihiro
    Ueno, Toshihide
    Takashima, Junpei
    Nakajima, Takahiro
    Yatabe, Yasushi
    Takeuchi, Kengo
    Hamada, Toru
    Haruta, Hidenori
    Ishikawa, Yuichi
    Kimura, Hideki
    Mitsudomi, Tetsuya
    Tanio, Yoshiro
    Mano, Hiroyuki
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1734 - 1739
  • [6] Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
    Costa, Daniel B.
    Shaw, Alice T.
    Ou, Sai-Hong I.
    Solomon, Benjamin J.
    Riely, Gregory J.
    Ahn, Myung-Ju
    Zhou, Caicun
    Shreeve, S. Martin
    Selaru, Paulina
    Polli, Anna
    Schnell, Patrick
    Wilner, Keith D.
    Wiltshire, Robin
    Camidge, D. Ross
    Crino, Lucio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1881 - 1888
  • [7] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
    Doebele, Robert C.
    Pilling, Amanda B.
    Aisner, Dara L.
    Kutateladze, Tatiana G.
    Le, Anh T.
    Weickhardt, Andrew J.
    Kondo, Kimi L.
    Linderman, Derek J.
    Heasley, Lynn E.
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1472 - 1482
  • [8] Felip E, 2015, J CLIN ONCOL, V33
  • [9] The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
    Friboulet, Luc
    Li, Nanxin
    Katayama, Ryohei
    Lee, Christian C.
    Gainor, Justin F.
    Crystal, Adam S.
    Michellys, Pierre-Yves
    Awad, Mark M.
    Yanagitani, Noriko
    Kim, Sungjoon
    Pferdekamper, AnneMarie C.
    Li, Jie
    Kasibhatla, Shailaja
    Sun, Frank
    Sun, Xiuying
    Hua, Su
    McNamara, Peter
    Mahmood, Sidra
    Lockerman, Elizabeth L.
    Fujita, Naoya
    Nishio, Makoto
    Harris, Jennifer L.
    Shaw, Alice T.
    Engelman, Jeffrey A.
    [J]. CANCER DISCOVERY, 2014, 4 (06) : 662 - 673
  • [10] Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
    Johnson, Ted W.
    Richardson, Paul F.
    Bailey, Simon
    Brooun, Alexei
    Burke, Benjamin J.
    Collins, Michael R.
    Cui, J. Jean
    Deal, Judith G.
    Deng, Ya-Li
    Dinh, Dac
    Engstrom, Lars D.
    He, Mingying
    Hoffman, Jacqui
    Hoffman, Robert L.
    Huang, Qinhua
    Kania, Robert S.
    Kath, John C.
    Lam, Hieu
    Lam, Justine L.
    Le, Phuong T.
    Lingardo, Laura
    Liu, Wei
    McTigue, Michele
    Palmer, Cynthia L.
    Sach, Neal W.
    Smeal, Tod
    Smith, Graham L.
    Stewart, Albert E.
    Timofeevski, Sergei
    Zhu, Huichun
    Zhu, Jinjiang
    Zou, Helen Y.
    Edwards, Martin P.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4720 - 4744
1234